Atipamezole structure
|
Common Name | Atipamezole | ||
---|---|---|---|---|
CAS Number | 104054-27-5 | Molecular Weight | 212.290 | |
Density | 1.1±0.1 g/cm3 | Boiling Point | 367.1±11.0 °C at 760 mmHg | |
Molecular Formula | C14H16N2 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 178.0±5.7 °C |
Use of AtipamezoleAtipamezole is a synthetic α2-adrenoceptor antagonist with a Ki of 1.6 nM. |
Name | 5-(2-ethyl-1,3-dihydroinden-2-yl)-1H-imidazole |
---|---|
Synonym | More Synonyms |
Description | Atipamezole is a synthetic α2-adrenoceptor antagonist with a Ki of 1.6 nM. |
---|---|
Related Catalog | |
Target |
Ki: 1.6 nM[1] |
In Vitro | The affinity of atipamezole for α2-adrenoceptors and its α2/α1 selectivity ratio are considerably higher than yohimbine. Atipamezole is not selective for subtypes of α2-adrenoceptors. It has negligible affinity for 5-HT1, 5-HT2 and I2 bindings sites[1]. |
In Vivo | Atipamezole is well tolerated in rodents. In anesthetized, normotensive rats, the cardiovascular effects of atipamezole (0.01–1 mg/kg, i.v.) are rather modest. Atipamezole is commonly used by veterinarians to awaken animals from sedation or anesthesia. Atipamezole increases sexual activity in rats and monkeys. In animals with sustained nociception, atipamezole increases pain-related responses by blocking the noradrenergic feedback inhibition of pain. Atipamezole at low doses has beneficial effects on alertness, selective attention, planning, learning, and recall in experimental animals, but not necessarily on short-term working memory[1]. |
References |
Density | 1.1±0.1 g/cm3 |
---|---|
Boiling Point | 367.1±11.0 °C at 760 mmHg |
Molecular Formula | C14H16N2 |
Molecular Weight | 212.290 |
Flash Point | 178.0±5.7 °C |
Exact Mass | 212.131348 |
PSA | 28.68000 |
LogP | 3.75 |
Vapour Pressure | 0.0±0.8 mmHg at 25°C |
Index of Refraction | 1.595 |
Storage condition | room temp |
Hazard Codes | Xi |
---|---|
RIDADR | NONH for all modes of transport |
Dexmedetomidine increases tau phosphorylation under normothermic conditions in vivo and in vitro.
Neurobiol. Aging 36 , 2414-28, (2015) There is developing interest in the potential association between anesthesia and the onset and progression of Alzheimer's disease. Several anesthetics have, thus, been demonstrated to induce tau hyper... |
|
Formulation, stability and pharmacokinetics of sugar-based salmon calcitonin-loaded nanoporous/nanoparticulate microparticles (NPMPs) for inhalation.
Int. J. Pharm. 483(1-2) , 6-18, (2015) A challenge exists to produce dry powder inhaler (DPI) formulations with appropriate formulation stability, biological activity and suitable physicochemical and aerosolisation characteristics that pro... |
|
Enhanced efficacy of the CDNF/MANF family by combined intranigral overexpression in the 6-OHDA rat model of Parkinson's disease.
Mol. Ther. 23(2) , 244-54, (2015) Cerebral Dopamine Neurotrophic Factor (CDNF) and Mesencephalic Astrocyte-derived Neurotrophic factor (MANF) are members of a recently discovered family of neurotrophic factors (NTFs). Here, we used in... |
Atipamezolum [Latin] |
MPV-1248 |
1H-imidazole, 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)- |
1H-Imidazole,4-(2-ethyl-2,3-dihydro-1H-inden-2-yl) |
Atipamezol [Spanish] |
1H-Imidazole, 5-(2-ethyl-2,3-dihydro-1H-inden-2-yl)- |
4-(2-Ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole |
Antisedan |
UNII-03N9U5JAF6 |
Atipamezole |